Target intelligence / Profile preview

Zinc finger and SCAN domain containing 16 pseudogene (ZSCAN16 pseudogene)

Target
ZSCAN16 pseudogene
Molecular classification
Other
01

Overview

Zinc finger and SCAN domain containing 16 pseudogene (ENSG00000273712) is a genomic sequence similar in structure to the ZSCAN16 gene, which encodes a transcription factor with both a zinc finger DNA-binding domain and a SCAN protein-protein interaction domain. However, as designated by the "pseudogene" status, ENSG00000273712 does not produce a functional protein product, and is not involved in active biological processes such as transcriptional regulation, cell signaling, or disease pathogenesis. Pseudogenes typically result from duplication or mutation of functional genes and do not serve as therapeutic targets, nor are they associated with characterized drug interactions, disease mechanisms, or validated biomarker roles. Supporting details and clarifications: - Not a therapeutic target: Pseudogenes like ENSG00000273712 are generally not considered therapeutic targets, as they do not encode functional proteins or participate directly in biological pathways relevant to pharmacology or disease. - Common confusion: The functional gene ZSCAN16 (without "pseudogene") is part of the zinc finger transcription factor family, which play roles in DNA binding and gene regulation. These proteins may be involved in cancer and other diseases, but the pseudogene variant is biologically inactive and not therapeutically relevant. - Aliases: The most significant aliases are the gene symbols ZSCAN16 pseudogene and ENSG00000273712, but common functional aliases (e.g., ZSCAN16, ZNF397) pertain to the protein-coding gene, not the pseudogene. - Molecular classification: Classified as "Other" since it does not fit into the categories of receptor, enzyme, transporter, transcription factor, ion channel, or histone modification due to lack of protein-coding activity. - Disease roles, drugs, mechanism of action, biomarkers, safety concerns: Not applicable for pseudogenes, as these relate to active gene products which interact with drugs or are implicated in disease mechanisms. Summary advice: If you require information on the functional protein-coding gene (ZSCAN16 rather than ZSCAN16 pseudogene), that gene is a transcription factor and may have disease relevance and molecular interactions. For the pseudogene (ENSG00000273712), no functional, biological, or disease-related characteristics are reported, and it should not be considered a therapeutic target.

Other names
ZSCAN16 pseudogeneENSG00000273712

Beyond the preview

Go deeper on Zinc finger and SCAN domain containing 16 pseudogene (ZSCAN16 pseudogene).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc finger and SCAN domain containing 16 pseudogene (ZSCAN16 pseudogene).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call